Altering Gut Microbiome May Improve ICI Outcomes in RCC
John SchieszerJun 5, 2018Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
Sunitinib alone noninferior to nephrectomy plus sunitinib with respect to overall survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2018 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
MONDAY, June 4, 2018 -- For patients with metastatic renal cell carcinoma classified as having intermediate or poor prognostic risk, sunitinib alone is noninferior to nephrectomy and sunitinib, according to a study published online June 3 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Standard of Care In Advanced Kidney Cancer, Surgery No Longer Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many With Metastatic Kidney Cancer Can Forego Surgery
Bryant FurlowJun 3, 2018For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 2, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:NKTR NYSE:BMY Source Type: news

Depleted metabolic enzymes promote tumor growth in kidney cancer
(University of Pennsylvania School of Medicine) By integrating data on the function of essential metabolic enzymes with genetic, protein, and metabolic abnormalities associated with " clear cell " renal cell carcinoma (ccRCC), researchers have determined that enzymes important in multiple pathways are universally depleted in ccRCC tumors. Kidney cancer, one of the ten most prevalent malignancies in the world, has increased in incidence over the last decade, likely due to rising obesity rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men
TUESDAY, May 8, 2018 -- Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma (RCC) in women, but not in men, according to a study published online April 20 in Diabetes Care. Rebecca E. Graff, Sc.D., from Harvard... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2018 Category: Pharmaceuticals Source Type: news

NSAID Use Associated With Shorter PFS, OS in Metastatic RCC
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Renal Cell Carcinoma Source Type: news

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

When TKI Sunitinib Can Be Discontinued in Metastatic RCC When TKI Sunitinib Can Be Discontinued in Metastatic RCC
Can sunitinib be discontinued in patients with stable metastatic renal cell carcinoma without negatively impacting outcomes?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Use of ibuprofen and similar NSAIDs may shorten life of patients
(IOS Press) Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Preferred First-line Treatment for Metastatic Kidney Cancer Preferred First-line Treatment for Metastatic Kidney Cancer
Indirect comparisons suggest that of available agents, cabozantinib or nivolumab plus ipilimumab may be the most effective first-line treatment for metastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Nivolumab/Ipilimumab Combo Bests Sunitinib in Advanced RCC
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology News Renal Cell Carcinoma Source Type: news

Payments to doctors linked to prescription practices for two cancer types
(UNC Lineberger Comprehensive Cancer Center) Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for metastatic renal cell carcinoma and for chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2018 Category: Cancer & Oncology Source Type: news

First-Line Avelumab/Axitinib Encouraging in Advanced RCC
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Combinations: The Future of Renal Cell Carcinoma Treatment?
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.04/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 5, 2018 Category: Urology & Nephrology Source Type: news

Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.04/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 4, 2018 Category: Urology & Nephrology Source Type: news

TIVO-1 Crossover: Tivozanib Active for Advanced RCC
Compared with sorafenib, tivozanib significantly improved PFS and OS, and yielded significantly higher ORRs, a crossover analysis of TIVO-1 found. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

New Standard of Care in Advanced Renal Cell Carcinoma? New Standard of Care in Advanced Renal Cell Carcinoma?
Combination immunotherapy significantly improved overall survival as compared to standard care with sunitinib as first-line therapy in patients with intermediate- and poor-risk disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment Options Expanding in Renal Carcinoma
First- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando. (Source: CancerNetwork)
Source: CancerNetwork - March 26, 2018 Category: Cancer & Oncology Authors: Roxanne Nelson Tags: Conferences/NCCN News Renal Cell Carcinoma Source Type: news

EU committee backs dosing changes for Bristol-Myers Squibb ’ s immunotherapy
A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today. The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for patients with advanced melanoma and previously-treated renal cell carcinoma. The committee also backed a shorter dosing option of 240-mg infused over 30 minutes every two weeks for Opdivo’s six approved monotherapy indications in...
Source: Mass Device - March 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Oncology Pharmaceuticals Regulatory/Compliance Wall Street Beat Bristol-Myers Squibb Co. Source Type: news

Certain Patient Subgroups May Benefit from Partial vs Radical Nephrectomy
In this large Chinese study, in certain subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Certain RCC Subgroups May Benefit From Partial vs Radical Nephrectomy
In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Antibiotics Could Reduce Diarrhea, Improve Outcomes in Metastatic RCC
Patients who received Bacteroides-targeting antibiotics had a median PFS of 18 months compared with 8 months in patients with no antibiotic use. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Infection News Renal Cell Carcinoma Source Type: news

45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
A 45-year-old female presents with gross hematuria 5 days after a laparoscopic partial nephrectomy for renal cell cancer. What is your diagnosis? (Source: CancerNetwork)
Source: CancerNetwork - March 1, 2018 Category: Cancer & Oncology Authors: Brian Morse, MD Tags: Image IQ Source Type: news

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with response to anti–PD-1 monotherapy, we performed whole-exome sequencing of metastatic ccRCC from 35 patients. We found that clinical benefit was associated with loss-of-function mutations in the PBRM1 gene (P = 0.012), which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. We confirmed this finding in an independent validation cohort of 63 c...
Source: ScienceNOW - February 15, 2018 Category: Science Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bosse, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, Tags: Medicine, Diseases reports Source Type: news

' Unprecedented' 73% Response Rate With Combo in Untreated RCC'Unprecedented' 73% Response Rate With Combo in Untreated RCC
The combination of an immunotherapy and a VEGF inhibitor for the initial treatment of advanced renal cell carcinoma yielded groundbreaking results. And it is not intolerably toxic.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer Support for Upfront Immunotherapy in Advanced Renal Cell Cancer
Atezolizumab plus bevacizumab improves progression-free survival with greater tolerability than standard sunitinib in advanced kidney cancer in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Clinical Decision-Making for Immunotherapy in Metastatic RCC Clinical Decision-Making for Immunotherapy in Metastatic RCC
Should immunotherapy be considered as a first-line treatment strategy for metastatic renal cell carcinoma?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Lymphadenectomy in Renal Cell Carcinoma: No Benefit? Lymphadenectomy in Renal Cell Carcinoma: No Benefit?
A secondary analysis of the ASSURE trial reveals that lymph node removal does not improve survival in high-risk renal cell carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."01/02/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 22, 2017 Category: Urology & Nephrology Source Type: news

U.S. FDA Approval of CABOMETYX ® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.12/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2017 Category: Urology & Nephrology Source Type: news

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for the expanded indication of patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Results from Alliance CABOSUN trial lead to US FDA approval of extended indication
(Alliance for Clinical Trials in Oncology) The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 19, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Eisai ’s Kisplyx for renal cell carcinoma
Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.12/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2017 Category: Urology & Nephrology Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news